ARTIA Reconstructive Tissue Matrix for Breast Reconstruction

Recruiting at 9 trial locations

Overseen By ABBVIE CALL CENTER

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Recruiting

Sponsor: AbbVie

Disqualifiers: Uncontrolled diabetes, Compromised wound healing, others

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

The purpose of this study is to evaluate the safety and effectiveness of ARTIA in adult participants undergoing immediate, two-stage, implant-based breast reconstruction post-mastectomy.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment ARTIA Reconstructive Tissue Matrix for breast reconstruction?

The study on Artia™ tissue matrix suggests it is used in breast reconstruction, but there is limited direct clinical data on its effectiveness. However, acellular dermal matrices (ADMs) like Artia™ are commonly used in breast reconstruction and are believed to improve aesthetic outcomes, although this is often based on surgeon opinion rather than extensive clinical trials. ^{1 2 3 4 5}

How is the ARTIA Reconstructive Tissue Matrix treatment different from other breast reconstruction treatments?

ARTIA Reconstructive Tissue Matrix is unique because it is a porcine (pig-derived) acellular dermal matrix (ADM) that retains the natural structure of the extracellular matrix (ECM), which helps in rapid integration with the body and supports cellular growth. This makes it particularly suitable for breast reconstruction, especially in cases where radiation has been used, as it mimics the biomechanics of human tissue. ^{1 6 7 8 9}

Research Team

ABBVIE INC.

Principal Investigator

AbbVie

Eligibility Criteria

This trial is for adults planning to have a mastectomy and immediate two-stage breast reconstruction. Participants must be willing to undergo the procedure using ARTIA, a reconstructive tissue matrix, or opt for no additional materials.

Inclusion Criteria

I am willing to have breast reconstruction with or without a specific technique immediately.

I am scheduled for a mastectomy on one or both breasts.

Exclusion Criteria

I have breast cancer and am not planning to have, or haven't had all the tumor removed by surgery.

I have a condition like uncontrolled diabetes that affects how my wounds heal.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Stage 1

Participants undergo the first stage of implant-based breast reconstruction with or without ARTIA Tissue Matrix

Up to 18 months

Treatment Stage 2

Participants undergo the second stage of implant-based breast reconstruction

Up to 18 months

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessment of satisfaction and complications

Up to 36 months

Treatment Details

Interventions

• ARTIA (Reconstructive Tissue Matrix)

Trial Overview The study tests the safety and effectiveness of ARTIA Reconstructive Tissue Matrix in breast reconstruction after mastectomy compared with traditional methods without this material.

Participant Groups

Group I: Non-Acellular Dermal Matrix (ADM) Control Group Experimental Treatment 1 Intervention

Breast reconstruction without ADM.

Group II: Acellular Dermal Matrix Experimental Treatment 1 Intervention

Breast reconstruction with ARTIA Tissue Matrix.

Who Is Running the Clinical Trial?

AbbVie

Lead Sponsor

Trials

1,079

Recruited

535,000+

Founded

2013

Headquarters

North Chicago, USA

Known For

Immunology treatments

Top Products

Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)

Dr. Roopal Thakkar

AbbVie

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

Robert A. Michael

AbbVie

Chief Executive Officer

Bachelor's degree in Finance from the University of Illinois

Findings from Research

In a study of 59 patients undergoing direct-to-implant breast reconstruction with acellular dermal matrix, 35 patients (59%) experienced surgical complications, highlighting a significant risk associated with this technique.

Larger mastectomy weight was identified as a key predictor of complications, suggesting that DTI ADM-assisted reconstruction may be safer for patients with small to moderate breast sizes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Predictors of complications after direct-to-implant breast reconstruction with an acellular dermal matrix from a multicentre randomized clinical trial. Negenborn, VL., Dikmans, REG., Bouman, MB., et al.[2019]

In a study involving 38 patients, the use of acellular dermal matrix (ADM) in tissue expander/implant-based breast reconstruction improved overall aesthetic scores by an average of 12.1%, with significant enhancements in breast contour, implant placement, and inframammary fold definition.

The findings suggest that incorporating ADM not only leads to better aesthetic outcomes, which may justify its cost, but also indicates potential additional benefits, warranting further research for more definitive guidelines on its use.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Does acellular dermal matrix really improve aesthetic outcome in tissue expander/implant-based breast reconstruction? Ibrahim, AM., Koolen, PG., Ganor, O., et al.[2018]

In a study comparing 29 patients undergoing subpectoral breast reconstruction to 34 patients receiving prepectoral reconstruction with anterior implant coverage, both methods showed similar complication rates, indicating that the new technique is safe.

The prepectoral approach resulted in a shorter drain removal period and improved breast symmetry, suggesting it may offer functional and cosmetic advantages over traditional methods, although subjective satisfaction levels were similar between the two groups.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Prepectoral breast reconstruction with complete anterior implant coverage using a single, large, square-shaped acellular dermal matrix. Hong, HK., Kim, YH., Lee, JS., et al.[2022]

A systematic review of 45 studies involving 5089 patients found that animal-derived acellular dermal matrices (ADMs), particularly Braxon®, are commonly used in prepectoral direct-to-implant breast reconstruction, with specific patient criteria such as a subcutaneous layer > 1 cm and no prior radiotherapy being important for successful outcomes.

The study identified increased complication risks in smokers, patients who had radiation treatment, those with larger breast volumes, and those requiring axillary dissection, while the effects of diabetes, high body mass index, and breast implant size on outcomes were inconclusive.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Immediate post-mastectomy prepectoral breast reconstruction with animal derived acellular dermal matrices: A systematic review. Tellarini, A., Garutti, L., Corno, M., et al.[2023]

In a study of 84 breast reconstructions, the overall rate of prosthesis implant removal was 21.4%, with significantly higher rates of 52.17% in smokers compared to 9.84% in non-smokers, indicating that smoking is a major risk factor for reconstruction failure.

Patients who had undergone ipsilateral breast radiation therapy (IBRT) also faced increased risks of implant removal, particularly if the radiation was administered after immediate breast reconstruction, suggesting that both smoking and IBRT should be considered when evaluating candidates for this type of reconstruction.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Breast reconstruction with silicone prosthesis and acellular dermal matrix of porcine origin: Retrospective study of 84 cases. Pouzet, L., Hotton, J., François, C., et al.[2022]

References

1. Netherlands pubmed.ncbi.nlm.nih.gov

Implant-based breast reconstruction with Artia™ tissue matrix. [2020]

2. England pubmed.ncbi.nlm.nih.gov

BROWSE: A multicentre comparison of nine year outcomes in acellular dermal matrix based and complete submuscular implant-based immediate breast reconstruction-aesthetics, capsular contracture and patient reported outcomes. [2022]

3. England pubmed.ncbi.nlm.nih.gov

Predictors of complications after direct-to-implant breast reconstruction with an acellular dermal matrix from a multicentre randomized clinical trial. [2019]

4. United States pubmed.ncbi.nlm.nih.gov

Does acellular dermal matrix really improve aesthetic outcome in tissue expander/implant-based breast reconstruction? [2018]

5. China (Republic : 1949- ) pubmed.ncbi.nlm.nih.gov

The relationship of human acellular dermal matrix thickness on complication rate and patient-reported outcomes in implant-based immediate breast reconstruction. [2022]

6. United States pubmed.ncbi.nlm.nih.gov

The Biointegration of a Porcine Acellular Dermal Matrix in a Novel Radiated Breast Reconstruction Model. [2021]

7. England pubmed.ncbi.nlm.nih.gov

Prepectoral breast reconstruction with complete anterior implant coverage using a single, large, square-shaped acellular dermal matrix. [2022]

8. Netherlands pubmed.ncbi.nlm.nih.gov

Immediate post-mastectomy prepectoral breast reconstruction with animal derived acellular dermal matrices: A systematic review. [2023]

9. France pubmed.ncbi.nlm.nih.gov

Breast reconstruction with silicone prosthesis and acellular dermal matrix of porcine origin: Retrospective study of 84 cases. [2022]